These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8249088)

  • 1. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis.
    di Martino L; Raimondi F; Scotti S; Davidson RN; Gradoni L; Giacchino R
    Trans R Soc Trop Med Hyg; 1993; 87(4):477. PubMed ID: 8249088
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL
    Clin Infect Dis; 1995 Jan; 20(1):191. PubMed ID: 7727652
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus.
    Laguna F; Torre-Cisneros J; Moreno V; Villanueva JL; Valencia E
    Clin Infect Dis; 1995 Sep; 21(3):711-2. PubMed ID: 8527591
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B.
    Gokhale PC; Kshirsagar NA; Khan MU; Pandya SK; Meisheri YV; Thakur CP; Choudhary CB
    Trans R Soc Trop Med Hyg; 1994; 88(2):228. PubMed ID: 8036684
    [No Abstract]   [Full Text] [Related]  

  • 9. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis.
    Castagnola E; Davidson RN; Fiore P; Tasso L; Rossi G; Mangraviti S; Di Martino L; Scotti S; Cascio A; Pempinello R; Gradoni L; Giacchino R
    Trans R Soc Trop Med Hyg; 1996; 90(3):317-8. PubMed ID: 8758092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
    Lopez Dupla M; Gil Aguado A; Lavilla Uriol P; Pintado Garcia V; Valencia Ortega E; Martinez Martinez P; Garcia-Puig J
    J Antimicrob Chemother; 1993 Oct; 32(4):657-9. PubMed ID: 8288512
    [No Abstract]   [Full Text] [Related]  

  • 11. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
    Karande SC; Boby KF; Lahiri KR; Jain MK; Kshirsagar NA; Gokhale PC; Pandya SK
    Trop Doct; 1995 Apr; 25(2):80-1. PubMed ID: 7778200
    [No Abstract]   [Full Text] [Related]  

  • 15. Visceral leishmaniasis: rapid response to AmBisome treatment.
    Smith OP; Hann IM; Cox H; Novelli V
    Arch Dis Child; 1995 Aug; 73(2):157-9. PubMed ID: 7574862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral leishmaniasis following treatment with liposomal amphotericin B.
    McBride M; Linney M; Claydon EJ; Weber J
    Clin Infect Dis; 1994 Aug; 19(2):362. PubMed ID: 7986926
    [No Abstract]   [Full Text] [Related]  

  • 17. Visceral leishmaniasis treated with liposomal amphotericin B.
    Catania S; Aiassa C; Tzahtzoglou S; Catania N; Tucciarone L; Antimi A; Ragni G; Clerico A
    Pediatr Infect Dis J; 1999 Jan; 18(1):73-4. PubMed ID: 9951989
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
    Croft SL; Davidson RN; Thornton EA
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 20. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.